Atlas Trials

Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function

Clinical trial NCT06004661 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT06004661
Sponsor
Novartis Pharmaceuticals
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Start date
2024-04-04
Primary completion
2026-12-14
Enrollment
23

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.